Impact of hepatitis B and hepatitis C virus infections on patients and allograft outcomes in renal transplant recipients: a single center study.
Hepatitis C virus (HCV) and hepatitis B virus (HBV) infections occur frequently among end-stage renal disease (ESRD) patients. We analyzed our data to address concern that these patients are at increased risk for mortality or allograft dysfunction after renal transplantation compared with noninfected patients. We retrospectively compared outcomes and survivals among 1350 patients who received renal allografts from 1990 to 2006. Fourteen patients were positive for both hepatitis B surface antigen (HBsAg) and HCV antibody (anti-HCV; group 1); 23 were HBsAg-positive and anti-HCV-negative (group 2); 29 were HBsAg-negative and anti-HCV-positive (group 3); and 1284 were negative for both markers (group 4). With respect to mean serum creatinine, there were significant differences between groups 1 and 4 (P < .01), and groups 2 and 4 (P < .01), but no significant difference between groups 3 and 4. With respect to graft survival, there were significant differences between groups 1 and 4 (P < .01), and between groups 2 and 4 (P < .01). There was no significant difference for survival among groups. HBV or HCV infections are not a contraindication to kidney transplantation in Iranian patients; they had no effect on patient survival. However, allograft outcomes were worse among HBV- or HCV-infected patients.